1921
Volume 100, Issue 4
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

A panel of experts from the Infectious Disease Society of America and The American Society of Tropical Medicine and Hygiene recently published guidelines for management of neurocysticercosis, showing that clinical manifestations as well as the stage of involution and the anatomical location of parasites must be taken into account before the start of a rational therapy. Soon thereafter, isolated opinions attempted to discredit these guidelines, arguing insufficient or inadequate evidence and suggesting that they should not be followed worldwide. In view of these conflicting reports, it is appropriate to review the origin and evolution of the controversy on the medical treatment of neurocysticercosis.

Loading

Article metrics loading...

The graphs shown below represent data from March 2017
/content/journals/10.4269/ajtmh.18-0921
2019-02-11
2020-09-25
Loading full text...

Full text loading...

/deliver/fulltext/14761645/100/4/tpmd180921.html?itemId=/content/journals/10.4269/ajtmh.18-0921&mimeType=html&fmt=ahah

References

  1. White AC, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE, 2018. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Am J Trop Med Hyg 98: 945966.
    [Google Scholar]
  2. White AC, Coyle CM, Rajshekhar V, Singh G, Hauser WA, Mohanty A, Garcia HH, Nash TE, 2018. Diagnosis and treatment of neurocysticercosis: 2017 clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 66: 11591163.
    [Google Scholar]
  3. Carpio A, Fleury A, Kelvin EA, Romo ML, Abraham R, Tellez-Zenteno J, 2018. New guidelines for the diagnosis and treatment of neurocysticercosis: a difficult proposal for patients in endemic countries. Expert Rev Neurother 18: 743747.
    [Google Scholar]
  4. Sotelo J, Penagos P, Escobedo F, Del Brutto OH, 1988. Short course of albendazole therapy for neurocysticercosis. Arch Neurol 45: 11301133.
    [Google Scholar]
  5. Robles C, Chavarría M, 1979. Presentación de un caso clínico de cisticercosis cerebral curado médicamente con un nuevo fármaco: praziquantel. Salud Pub Mex 21: 603618.
    [Google Scholar]
  6. Gómez JG, Peña G, Patiño R, Pradilla G, 1981. Neurocysticercosis treated with praziquantel. Neurol Colombia 5: 665670.
    [Google Scholar]
  7. Botero D, Castaño S, 1982. Treatment of cysticercosis with praziquantel in Colombia. Am J Trop Med Hyg 31: 811821.
    [Google Scholar]
  8. Spina-França A, Nobrega JPS, Livramento JA, Machado LR, 1982. Administration of praziquantel in neurocysticercosis. Tropenmed Parasitol 33: 14.
    [Google Scholar]
  9. Kramer LD, 1995. Medical treatment of cysticercosis—ineffective. Arch Neurol 52: 101102.
    [Google Scholar]
  10. Wadia N, Desai S, Bhatt M, 1988. Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel. Brain 111: 597614.
    [Google Scholar]
  11. Sotelo J, Escobedo F, Rodríguez-Carbajal J, Torres B, Rubio-Donnadieu F, 1984. Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 310: 10011007.
    [Google Scholar]
  12. Sotelo J, Torres B, Rubio-Donnadieu F, Escobedo F, Rodríguez-Carbajal J, 1985. Praziquantel in the treatment of neurocysticercosis: long-term follow-up. Neurology 35: 752754.
    [Google Scholar]
  13. Carpio A, Santillán F, León P, Flores C, Hauser WA, 1995. Is the course of neurocysticercosis modified by treatment with antihelmintic agents? Arch Intern Med 155: 19821988.
    [Google Scholar]
  14. Carpio A, Santillán F, León P, Borrero A, 1988. New treatment of brain cysticercosis with albendazole. Ann Neurol 24: 144.
    [Google Scholar]
  15. Carpio A, Kelvin EA, Begiella E, Leslie D, Leon P, Andrews H, Hauser WA; Ecuadorian Neurocysticercosis Group, 2008. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry 79: 10501055.
    [Google Scholar]
  16. Carpio A, Hauser WA, 2002. Prognosis of seizure recurrence in patients with newly diagnosed neurocysticercosis. Neurology 59: 17301734.
    [Google Scholar]
  17. Vazquez V, Sotelo J, 1992. The course of seizures after treatment for cerebral cysticercosis. N Engl J Med 327: 696701.
    [Google Scholar]
  18. Del Brutto OH, Santibáñez R, Noboa CA, Aguirre I, Díaz E, Alarcón TA, 1992. Epilepsy due to neurocysticercosis: analysis of 203 patients. Neurology 42: 389392.
    [Google Scholar]
  19. Carpio A, Escobar A, Hauser WA, 1998. Cysticercosis and epilepsy: a critical review. Epilepsia 39: 10251040.
    [Google Scholar]
  20. Garcia HH, Pretell EJ, Gilman RH, Martinez SM, Moulton LH, Del Brutto OH, Herrera G, Evans CWA, Gonzalez AE, 2004. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N Engl J Med 350: 249258.
    [Google Scholar]
  21. Romo ML, Wyka K, Carpio A, Leslie D, Andrews H, Bagiella E, Hauser WA, Kevin EA; Ecuadorian Neurocysticercosis Group, 2015. The effect of albendazole treatment on seizure outcomes in patients with symptomatic neurocysticercosis. Trans R Soc Trop Med Hyg 109: 738746.
    [Google Scholar]
  22. Baranwal AK, Singhi PD, Khandelwal N, Singhi SC, 1998. Albendazole therapy in children with focal seizures and single small enhancing computerized tomographic lesions: a randomized, placebo-controlled double-blind trial. Pediatr Infect Dis 17: 696700.
    [Google Scholar]
  23. Gogia S, Talkdar B, Choudhury V, Arora BS, 2003. Neurocysticercosis in children: clinical findings and response to albendazole therapy in a randomized, double-blind, placebo-controlled trial in newly diagnosed cases. Trans R Soc Trop Med Hyg 97: 416421.
    [Google Scholar]
  24. Del Brutto OH, Roos KL, Coffey CS, Garcia HH, 2006. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 145: 4351.
    [Google Scholar]
  25. Mazumdar M, Pandharipande P, Poduri A, 2007. Does albendazole affect seizure remission and computed tomography response in children with neurocysticercosis? A systematic review and meta-analysis. J Child Neurol 22: 135142.
    [Google Scholar]
  26. Otte WM, Singla M, Sander JW, Singh G, 2013. Drug therapy for solitary cysticercus granuloma: a systematic review and meta-analysis. Neurology 80: 152162.
    [Google Scholar]
  27. Zhao BC et al., 2016. Albendazole and corticosteroids for the treatment of solitary cysticercus granuloma: a network meta-analysis. PLoS Negl Trop Dis 10: e0004418.
    [Google Scholar]
  28. Baird RA, Wiebe S, Zunt JR, Halperin JJ, Gronseth G, Roos KL, 2013. Evidence-based guideline: treatment of parenchymal neurocysticercosis: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 80: 14241429.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.18-0921
Loading
  • Received : 18 Nov 2018
  • Accepted : 04 Jan 2019
  • Published online : 11 Feb 2019
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error